Nektar Therapeutics | NKTR - 市值



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 15.95B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


市值 更改 日
Agios Pharmaceuticals USD 2.01B 423M 2026-03
ALKERMES USD 5.53B 909M 2026-05
Alterity Therapeutics Limited AUD 40M 16M 2026-05
Amgen USD 189.89B 13.64B 2026-03
Baxter International USD 8.67B 1.15B 2026-03
BioCryst Pharmaceuticals USD 1.66B 64M 2025-12
Biogen USD 26.9B 1.09B 2026-03
Bristol-Myers Squibb USD 123.83B 14.02B 2026-03
Cara Therapeutics USD 366M 338M 2025-09
Cipla INR 1.22T 6.47B 2025-12
Dr.Reddys Laboratories INR 1.06T 39.78B 2025-12
Eisai JPY 1.31T 140.95B 2025-12
Eli Lilly USD 869.02B 146.97B 2026-03
Esperion Therapeutics USD 885M 351M 2025-12
Exelixis USD 12.9B 1.15B 2026-05
Gilead Sciences USD 152.28B 14.55B 2025-12
GlaxoSmithKline GBP 83.8B 9.44B 2026-03
Halozyme Therapeutics USD 7.91B 664M 2025-12
Incyte USD 21.73B 3B 2026-05
Ionis Pharmaceuticals USD 12.46B 356M 2026-03
Karyopharm Therapeutics USD 956M 821M 2026-05
MacroGenics USD 102M 4M 2025-12
Merck USD 297.1B 35.84B 2026-03
Nektar Therapeutics USD 15.62B 14.76B 2026-05
Neurocrine Biosciences USD 13.34B 800M 2026-05
Novartis USD 232.75B 75B 2026-05
Pfizer USD 148.08B 6.51B 2026-05
Roche Holding CHF 266.34B 55.46B 2025-12
Sarepta Therapeutics USD 2.26B 238M 2025-12
Takeda JPY 7.64T 774.9B 2025-12
Teva Pharmaceutical Industries USD 34.27B 2.14B 2026-03
Xencor USD 1.09B 256M 2025-12